GLP-1 ANALOGUES IN OBESITY THERAPY: CURRENT EVIDENCE AND FUTURE DIRECTIONS – A SYSTEMATIC REVIEW
Abstract
Introduction: Obesity remains one of the most significant global health problems, contributing to increased morbidity, premature mortality, and escalating healthcare expenditures. While lifestyle modification continues to serve as the foundation of therapy, its long-term effects are often modest and difficult to sustain. Bariatric surgery, though highly effective, is invasive and cannot be applied to all patients. For this reason, there is a pressing need for safe and effective pharmacological options. In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as highly promising agents for the treatment of obesity.
Materials and Methods: A targeted literature search was conducted in PubMed/MEDLINE and PubMed Central covering studies published from 2012 through 2024. Search terms included”GLP-1 receptor agonists, ”“liraglutide, ”“semaglutide, ”“tirzepatide, ” and”obesity.” Eligible studies were randomized controlled trials (RCTs), systematic reviews, and meta-analyses reporting outcomes related to weight reduction and metabolic parameters. Ten key publications were selected for detailed analysis, encompassing pivotal trials of liraglutide, semaglutide, and tirzepatide.
Results: Treatment with liraglutide 3.0 mg daily resulted in average weight reductions of 7–8% over treatment periods ranging from 56 to 104 weeks. Semaglutide 2.4 mg once weekly achieved losses of 14–17% in both adult and adolescent populations. Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrated unprecedented efficacy, with reductions of up to 20.9% at higher doses. Across all agents, improvements were observed in glycemic control, blood pressure, and lipid metabolism. The most frequently reported adverse events were gastrointestinal, including nausea, vomiting, and diarrhea, typically mild, transient, and dose-dependent.
Conclusions: GLP-1RAs represent a paradigm shift in obesity pharmacotherapy, providing substantial and clinically relevant weight loss together with broader cardiometabolic benefits. Nonetheless, weight regain following treatment discontinuation, high financial costs, and the need for long-term safety data remain important challenges. Future research should focus on sustaining treatment effects, evaluating newer incretin-based agents, and improving accessibility in order to maximize their global clinical impact.
References
World Health Organization. (2021). Obesity and overweight. Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Bray, G. A., Kim, K. K., & Wilding, J. P. H. (2017). Obesity: A chronic relapsing progressive disease process. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 10, 493–498. https://doi.org/10.2147/DMSO.S113454
Hruby, A., & Hu, F. B. (2015). The epidemiology of obesity: A big picture. PharmacoEconomics, 33(7), 673–689. https://doi.org/10.1007/s40273-014-0243-x
Blüher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews Endocrinology, 15(5), 288–298. https://doi.org/10.1038/s41574-019-0176-8
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., … & Yanovski, S. Z. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation, 129(25 Suppl 2), S102–S138. https://doi.org/10.1161/01.cir.0000437739.71477.ee
Wing, R. R., & Phelan, S. (2005). Long-term weight loss maintenance. American Journal of Clinical Nutrition, 82(1 Suppl), 222S–225S. https://doi.org/10.1093/ajcn/82.1.222S
Sjostrom, L., Narbro, K., Sjostrom, C. D., Karason, K., Larsson, B., Wedel, H., … & Carlsson, L. M. (2007). Effects of bariatric surgery on mortality in Swedish obese subjects. New England Journal of Medicine, 357(8), 741–752. https://doi.org/10.1056/NEJMoa066254
Buchwald, H., & Oien, D. M. (2013). Metabolic/bariatric surgery worldwide 2011. Obesity Surgery, 23(4), 427–436. https://doi.org/10.1007/s11695-012-0864-0
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., … & Skjøth, T. V. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., … & Kushner, R. F. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Grant, M. J., & Booth, A. (2009). A typology of reviews: An analysis of 14 review types and associated methodologies. Health Information & Libraries Journal, 26(2), 91–108. https://doi.org/10.1111/j.1471-1842.2009.00848.x
Munn, Z., Peters, M. D., Stern, C., Tufanaru, C., McArthur, A., & Aromataris, E. (2018). Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Medical Research Methodology, 18(1), 143. https://doi.org/10.1186/s12874-018-0611-x
Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (Eds.). (2022). Cochrane handbook for systematic reviews of interventions (version 6.3). Cochrane. https://training.cochrane.org/handbook
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., … & Moher, D. (2009). The quality of reporting of meta-analyses included in systematic reviews of randomized controlled trials. Health Technology Assessment, 13(53), 1–134. https://doi.org/10.3310/hta13530
Higgins, J. P., & Green, S. (Eds.). (2011). Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane Collaboration.
Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E., … & Rossner, S. (2012). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity, 36(6), 843–854. https://doi.org/10.1038/ijo.2011.158
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., … & Rubino, D. M. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, in combination with intensive behavioral therapy (STEP 3). The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., … & Wadden, T. A. (2022). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., … & Wilding, J. P. H. (2022). Once-weekly semaglutide in adolescents with obesity (STEP TEENS). New England Journal of Medicine, 387(24), 2245–2257. https://doi.org/10.1056/NEJMoa2208601
Kahal, H., O’Hare, J. P., & Kilpatrick, E. S. (2024). GLP-1 receptor agonists and cardiovascular outcomes in obesity without diabetes. Cardiovascular Diabetology, 23(1), 14. https://doi.org/10.1186/s12933-024-01948-1
Piątkiewicz, P., Bieńkiewicz, M., & Czupryniak, L. (2024). Emerging therapies for obesity: GLP-1 receptor agonists and beyond. Endokrynologia Polska, 75(2), 97–108. https://doi.org/10.5603/EP.a2024.0012
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M., … & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., … & Yusuf, S. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
Frias, J. P., Nauck, M. A., Van J., Kutner, M. E., Cui, X., Benson, C., … & Urva, S. (2021). Efficacy and safety of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes (SURPASS-1). The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., … & Haupt, A. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. https://doi.org/10.1016/j.molmet.2018.09.009
Views:
103
Downloads:
41
Copyright (c) 2025 Natalia Strumnik, Bartosz Michał Skorupski, Oliwia Sójkowska-Sławińska, Anna Leśniewska, Patryk Macuk, Michał Gniedziejko, Jakub Roszak, Paulina Bernecka, Jakub Hamouta, Wiktor Doroszuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
